Treatment of Parkinson's Disease with Nocturia and Nocturnal Polyuria

Nocturia and nocturnal polyuria are recognised complications in Parkinson's disease that require specific clinical management alongside the underlying neurological condition.

Clinical Scenario

This protocol applies to patients with Parkinson's disease who present with nocturia nocturnal polyuria. Both conditions may significantly disrupt sleep and quality of life in this population and call for a structured, targeted approach.

Treatment Approach (partial overview)

Management begins with non-pharmacological measures to reduce overnight urine production, followed — where indicated — by specific pharmacological options tailored to whether the dominant issue is nocturnal polyuria or reduced bladder capacity. The complete algorithm, including the sequence and criteria for each intervention, is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

For non-pharmacological treatment of nocturia, patients should be advised to restrict fluid intake in the late afternoon and evening, avoid evening alcohol consumption, and aim for an upper body elevation of 10–20° while sleeping.
Desmopressin therapy may be considered for treating nocturnal polyuria under close monitoring of blood pressure, serum electrolytes, and body weight.
For treatment of nocturia due to reduced bladder capacity in Parkinson's patients, therapy with antimuscarinics such as Solifenacin, Trospium, or Darifenacin may be considered.

DOI: 10.1186/s42466-024-00325-4

View source ↗